-
H.C. Wainwright Upgrades Shattuck Labs (STTK) to Buy
-
Shattuck Labs (STTK) PT Raised to $2 at Citi
-
Shattuck Labs Inc. (STTK) files for 105.27M share offering by selling stockholders
-
Wedbush Starts Shattuck Labs (STTK) at Outperform
-
H.C. Wainwright Reiterates Neutral Rating on Shattuck Labs (STTK)
-
Shattuck Labs receives FDA clearance to begin SL-325 trial for IBD
-
Shattuck Labs (STTK) PT Lowered to $2 at Leerink Partners
-
Shattuck Labs, Inc. (STTK) Misses Q1 EPS by 4c
-
H.C. Wainwright Reiterates Neutral Rating on Shattuck Labs (STTK)
-
Leerink Partners Starts Shattuck Labs (STTK) at Outperform
-
Shattuck Labs (STTK) Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of ECCO
-
Shattuck Labs Inc. (STTK) Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
-
Citi Downgrades Shattuck Labs Inc. (NASDAQ: STTK) to Neutral
-
H.C. Wainwright Downgrades Shattuck Labs (STTK) to Neutral
-
H.C. Wainwright Downgrades Shattuck Labs (STTK) to Neutral
-
TD Cowen Reiterates Buy Rating on Shattuck Labs (STTK)
-
Shattuck Labs (STTK) Provides Company Update and Announces SL-325
-
H.C. Wainwright Reiterates Buy Rating on Shattuck Labs (STTK)
-
BTIG Reiterates Neutral Rating on Shattuck Labs (STTK)
-
Shattuck Labs Inc. (STTK) to Join Russell 2000 and Russell 3000
-
Shattuck Labs (STTK) PT Lowered to $16 at H.C. Wainwright
-
Shattuck Labs (STTK) PT Lowered to $9 at Citi
-
Shattuck Labs Inc. (STTK) Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Trial of SL-172154
-
Shattuck Labs Inc. (STTK) Granted FDA Orphan Drug Designation for SL-172154

